Peter Ciriello takes over the reins at Vygon USA; Mirum Pharmaceuticals taps Ian Clements to the role of CFO
→ Peter Ciriello has climbed to the upper echelons of the French medical device maker Vygon Group. He will run the company’s US operations from the company’s headquarters in Pennsylvania and is also tasked with overseeing activities at the New Hampshire facility. Ciriello joined Vygon in 2018 and takes over from Les Davies, who served as CEO, Vygon UK and VP for the UK/North American region. Ciriello previously served as co-founder and managing partner at Clearwater Organic Farms.
→ After regaining two liver disease drugs from Shire and making its public debut with a $67.3 million IPO, Mirum Pharmaceuticals has promoted SVP, finance of communications Ian Clements to CFO. Clements joined the company in May 2019 after a stint as VP of investor relations at Dermira. He previously worked with Tobira, Avanir Pharmaceuticals, Sequenom and The Trout Group.
→ Disarm Therapeutics — incubated out of Atlas Venture’s Cambridge, MA hatching grounds and led by former CEO of Enzyvant Alvin Shih — has welcomed Scott Holmes as CFO. Holmes joins the company after a stint as CFO at Kiadis Pharma, where he led the acquisition of CytoSen Therapeutics. Before that, Holmes served at Keryx Biopharmaceuticals and AMAG Pharmaceuticals.
→ After signing off on €120 million deal to purchase Expedeon AG‘s proteomics and immunology business last November, Abcam has appointed Michael Baldock as CFO and board member. Baldock has taken the role after a stint as a founding partner at Ondra Partners, where he advised Abcam for several years. Baldock’s previously worked with HSBC, Lazard, Bentley Health Care, and SG Warburg.
→ Eye-focused Avellino Labs has named Chris Lehman as CFO. Lehman arrives at the company as it prepares to make its public debut on the Korean stock exchange. Most recently, Lehman served in the same position at Eureka Therapeutics. Lehman’s previous experience includes roles at Coherus Biosciences, Quintiles and Genencor International (acquired by DuPont de Nemours).
→ While preparing for the potential approval of their MultiStem cell therapy Athersys has tapped Ivor Macleod as CFO. Macleod served as CFO and CCO of Eisai before making the leap over to Athersys. Prior to that, he held roles at Merck, Hoffman-La Roche, and Boehringer Mannheim Therapeutics.
→ Wall Street newbie BioNTech — which obtained a €50 million (around $55 million) loan from the European Investment Bank last month — has appointed Ryan Richardson as CSO and managing director. Richardson joined the company in 2018 as SVP, corporate development & strategy. Before that, Richardson was at JP Morgan in London.
→ French life science VC Sofinnova Partners has promoted Michael Krel to partner in its industrial biotechnology team. Previously, he served as principal on the team, focusing on early-stage deals in Europe and North America. Krel joined the company as a senior associate in 2013.
→ Venrock has promoted two members of their tech team to the position of partner — Ethan Batraski and Racquel Bracken. Batraski joined the company in 2017 after stints at Facebook, Box and Yahoo! Bracken hopped over to Venrock in 2016, after serving as CEO of Federation Bio, leading a Series B round for Cyteir and a stint at Clovis Oncology. In addition, the company welcomed Todd Graham to the tech team as VP in Palo Alto. Graham makes the leap over to Venrock from Cisco.
→ Atlas-backed Dyne Therapeutics has brought on Molly White as VP, medical communications and advocacy. White previously served as the CEO of Myotonic (formerly Myotonic Dystrophy Foundation)
→ Former Gilead exec John Martin is hopping onto the board of directors at Sarepta Therapeutics — which secured a $1.15 billion DMD deal with Roche last month. Martin served a 20-year tenure as CEO of Gilead.
→ MIT professor Bob Langer — who, along with Dan Anderson, licensed siRNA delivery tech to Verseau for $50 million last October — has joined the scientific advisory board at cancer-focused GeneMedicine.
→ While bluebird bio begins rolling out its $1.8 million gene therapy Zyteglo in Europe, the company has tapped former Celgene exec Nicola Heffron to head its European operations. Heffron is succeeding Andrew Obenshain — new title of “chief of wings” — who is heading to the company’s Boston office to join CEO Nick Leschly.
→ After losing their CEO last month, Ipsen — which is grappling with an FDA hold on its lead rare disease drug palovarotene — has tapped former Merck Serono exec Steven Hildemann as EVP, chief medical officer, head of global medical affairs and pharmacovigilance. During his time at Merck, Hildemann served as CMO and SVP and head of global medical affairs and patient safety. His previous experience spans Merck/Schering Plough, Amgen and Pfizer/Pharmacia.